Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Cancer Cell

• Publication date

  2016-06-13

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ccell.2016.05.001PMID 27265505PMCID PMC4975533
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pathways Responsible for Human Autoantibody and Therapeutic Intravenous IgG Activity in Humanized Mice.

  2015cited by this paper
• Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect.

  2015influential reference
• Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies

  2015influential reference
• FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis.

  2015cited by this paper
• Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma

  2014cited by this paper
• OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy

  2014cited by this paper
• Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity.

  2014cited by this paper
• humanized mice to study FcγR function.

  2014cited by this paper
• Type I and type II Fc receptors regulate innate and adaptive immunity

  2014cited by this paper
• Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

  2013cited by this paper
• Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIaR131 and FcγRIIaH131

  2013cited by this paper
• Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

  2013cited by this paper
• Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors

  2013cited by this paper
• Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

  2013cited by this paper
• Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer

  2013influential reference
• Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo

  2013cited by this paper
• Agonistic CD40 Antibodies and Cancer Therapy

  2013cited by this paper
• Ex Vivo Assays of Dendritic Cell Activation and Cytokine Profiles as Predictors of In Vivo Effects in an Anti-Human CD40 Monoclonal Antibody ChiLob 7/4 Phase I Trial

  2013cited by this paper
• Engineered antibody Fc variant with selectively enhanced Fc gamma RIIb binding over both Fc gamma RIIaR131 and Fc gamma RIIaH131.

  2013cited by this paper
• Mouse model recapitulating human Fcγ receptor structural and functional diversity

  2012influential reference
• A general requirement for FcγRIIB co-engagement of agonistic anti-TNFR antibodies

  2012cited by this paper
• Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody

  2011cited by this paper
• Inhibitory Fcγ Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies

  2011influential reference
• Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors

  2010influential reference
• Anti-CD40L Immune Complexes Potently Activate Platelets In Vitro and Cause Thrombosis in FCGR2A Transgenic Mice

  2010cited by this paper
• A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia

  2010cited by this paper
• Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses.

  2009cited by this paper
• Interchain disulfide bonding in human IgG2 antibodies probed by site-directed mutagenesis.

  2009cited by this paper
• Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice

  2009cited by this paper
• Fcγ receptors as regulators of immune responses

  2008cited by this paper
• Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies.

  2008cited by this paper
• Fcgamma receptors as regulators of immune responses.

  2008cited by this paper
• Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

  2007cited by this paper
• Immunostimulatory monoclonal antibodies for cancer therapy

  2007cited by this paper
• FcgammaRIV: a novel FcR with distinct IgG subclass specificity.

  2005influential reference
• FcγRIV : A novel FcR with distinct IgG subclass specificity

  2005influential reference
• Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding

  2005cited by this paper
• Tracking CD40 signaling during germinal center development.

  2004cited by this paper
• FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy.

  2003cited by this paper
• CD40 Is Constitutively Expressed on Platelets and Provides a Novel Mechanism for Platelet Activation

  2003cited by this paper
• FcγRI-Deficient Mice Show Multiple Alterations to Inflammatory and Immune Responses

  2002cited by this paper
• FcgammaRI-deficient mice show multiple alterations to inflammatory and immune responses.

  2002cited by this paper
• A bacterial artificial chromosome library for sequencing the complete human genome.

  2001cited by this paper

• The broad spectrum of cancer and immunotherapy: achievements and limitations

  2026cites this paper
• Harnessing multivalency and FcγRIIB engagement to augment anti-CD27 immunotherapy

  2025cites this paper
• Innovative gene engineering and drug delivery systems for dendritic cells in cancer immunotherapy

  2025cites this paper
• Target cell adhesion limits macrophage phagocytosis and promotes trogocytosis.

  2025cites this paper
• Recombinant spider silk functionalized with a CD40 agonist shows improved capability to activate human B cells in vitro - A novel module for cancer immunotherapy.

  2025cites this paper
• Modulating checkpoint molecules in inflammatory bowel diseases as a new therapeutic strategy: a narrative review.

  2025cites this paper
• Targeting Myeloid Cells for Cancer Immunotherapy

  2025cites this paper
• SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile.

  2025cites this paper
• Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer.

  2025cites this paper
• Early Antibody-Mediated Immunity to Tuberculosis in Mice Requires NLRP3

  2025cites this paper
• An anti-CD47 antibody binds to a distinct epitope in a novel metal ion-dependent manner to minimize cross-linking of red blood cells

  2025cites this paper
• Emerging therapeutics targeting tumor-associated macrophages for the treatment of solid organ cancers

  2025cites this paper
• Facts and hopes of CD40 agonists as a cancer immunotherapy.

  2025cites this paper
• Development of a Tumor-Specific Multivalent CD40 Agonist Antibody FAPxCD40 for Cancer Therapy: Balancing Efficacy and Toxicity.

  2025cites this paper
• Target cell adhesion limits macrophage phagocytosis and promotes trogocytosis

  2025cites this paper
• CD32B1, a versatile non-signaling antibody-binding scaffold for enhanced T cell adhesion to tumor stromal cognate antigens

  2025cites this paper
• Systemic Immune Response to a CD40-Agonist Antibody in Nonhuman Primates.

  2024cites this paper
• Monoclonal Antibodies in Modern Medicine: Their Therapeutic Potential and Future Directions

  2024cites this paper
• Engineering antibodies with cancer‐associated binding sites

  2024cites this paper
• Combining anti-checkpoint immunotherapies and cancer vaccines as a novel strategy in oncological therapy: A review.

  2024cites this paper
• Linking Effector Function to Antitumor Monoclonal Antibody Efficacy.

  2024cites this paper
• Tumor necrosis factor superfamily signaling: life and death in cancer

  2024cites this paper
• Unraveling spontaneous humoral immune responses against human cancer: A road to novel immunotherapies.

  2024cites this paper
• Intratumoral Fc-optimized agonistic CD40 antibody induces tumor rejection and systemic antitumor immunity in patients with metastatic cancer

  2024cites this paper
• Clinical landscape of macrophage-reprogramming cancer immunotherapies

  2024cites this paper
• Reversible Chemical Modification of Antibody Effector Function Mitigates Unwanted Systemic Immune Activation

  2024cites this paper
• Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities

  2024cites this paper
• Crystal structures of human CD40 in complex with monoclonal antibodies dacetuzumab and bleselumab.

  2024cites this paper
• Fcγ-Receptor-Independent Controlled Activation of CD40 Canonical Signaling by Novel Therapeutic Antibodies for Cancer Therapy

  2024influential citation
• Genetically engineered IgG1 and nanobody oligomers acquire strong intrinsic CD40 agonism

  2024cites this paper
• The Antitumor Activities of Anti-CD47 Antibodies Require Fc-FcγR interactions

  2023cites this paper
• Agonist antibodies for cancer immunotherapy: History, Hopes and Challenges

  2023cites this paper
• FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment

  2023cites this paper
• M9657 is a bispecific tumor-targeted anti-CD137 agonist that induces MSLN-dependent antitumor immunity without liver inflammation.

  2023cites this paper
• Roles of Tumor-Associated Macrophages in Tumor Environment and Strategies for Targeting Therapy

  2023cites this paper
• Fcγ receptors and immunomodulatory antibodies in cancer

  2023cites this paper
• The antitumor activities of anti-CD47 antibodies require Fc-FcγR interactions.

  2023cites this paper
• Fc gamma receptors promote antibody-induced LILRB4 internalization and immune regulation of monocytic AML

  2023influential citation
• Dendritic cells as shepherds of T cell immunity in cancer.

  2023cites this paper
• Serum immunoglobulin and the threshold of Fc receptor-mediated immune activation

  2023cites this paper
• A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

  2023cites this paper
• Effect of posttranslational modifications and subclass on IgG activity: from immunity to immunotherapy

  2023cites this paper
• Signaling pathways involved in the biological functions of dendritic cells and their implications for disease treatment

  2023cites this paper
• Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB

  2023cites this paper
• Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectives

  2023cites this paper
• Cell targeting and immunostimulatory properties of a novel Fcγ-receptor-independent agonistic anti-CD40 antibody in rhesus macaques

  2023cites this paper
• Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy

  2023cites this paper
• IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer

  2023cites this paper
• Reducing affinity as a strategy to boost immunomodulatory antibody agonism

  2023cites this paper
• Fcγ-receptor-independent controlled activation of CD40 canonical signaling by novel therapeutic antibodies for cancer therapy

  2023influential citation
• Anti–PD-1 antibodies recognizing the membrane-proximal region are PD-1 agonists that can down-regulate inflammatory diseases

  2023cites this paper
• Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting

  2022cites this paper
• CD16+ fibroblasts foster a trastuzumab-refractory microenvironment that is reversed by VAV2 inhibition.

  2022cites this paper
• Unlocking the potential of agonist antibodies for treating cancer using antibody engineering.

  2022cites this paper
• FcγRs and Their Relevance for the Activity of Anti-CD40 Antibodies

  2022influential citation
• Finding the Right Heavy Chains for Immunostimulatory Antibodies

  2022cites this paper
• ICOS is upregulated on T cells following radiation and agonism combined with radiation results in enhanced tumor control

  2022cites this paper
• Structural Basis of a Novel Agonistic Anti-OX40 Antibody

  2022cites this paper
• Fcγ receptor–mediated cross-linking codefines the immunostimulatory activity of anti-human CD96 antibodies

  2022cites this paper
• Regulatory T Cell Depletion Using a CRISPR Fc-Optimized CD25 Antibody

  2022cites this paper
• Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines

  2022cites this paper
• Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy

  2022cites this paper
• Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: The Role of FcγRIIB Cross-Linking

  2022influential citation
• 2022 update on the scientific premise and clinical trials for IL‐15 agonists as cancer immunotherapy

  2022cites this paper
• Zooming in on dendritic cells for CD40 agonists

  2022cites this paper
• Clinical relevance of tumour-associated macrophages

  2022cites this paper
• Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires FcγRIIB and virus-antibody complex with bivalent interaction

  2022cites this paper
• The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation

  2022cites this paper
• Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering

  2022cites this paper
• Receptor Oligomerization and Its Relevance for Signaling by Receptors of the Tumor Necrosis Factor Receptor Superfamily

  2021cites this paper
• Analysis of FcγR-Dependent Agonism of Antibodies Specific for Receptors of the Tumor Necrosis Factor (TNF) Receptor Superfamily (TNFRSF).

  2021cites this paper
• The Current Landscape of Antibody-based Therapies in Solid Malignancies

  2021cites this paper
• APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application

  2021cites this paper
• A general Fc engineering platform for the next generation of antibody therapeutics

  2021cites this paper
• Agonistic CD40 Antibodies in Cancer Treatment

  2021cites this paper
• CD40 Agonist Targeted to Fibroblast Activation Protein α Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors

  2021cites this paper
• Fcγ receptors—Master regulators of antibody therapy

  2021cites this paper
• Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer

  2021cites this paper
• Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy

  2021cites this paper
• Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia

  2021cites this paper
• Development of Therapeutic Antibodies and Modulating the Characteristics of Therapeutic Antibodies to Maximize the Therapeutic Efficacy

  2021cites this paper
• Mediation of Tumor Cell Death by Naked Antibodies

  2021cites this paper
• Anti-CD40 Antibodies Fused to CD40 Ligand Have Superagonist Properties

  2021influential citation
• Agonist antibody discovery: experimental, computational, and rational engineering approaches.

  2021cites this paper
• Have Superagonist Properties Anti-CD40 Antibodies Fused to CD40 Ligand

  2021influential citation
• Tailoring Cationic Helical Polypeptides for Efficient Cytosolic Protein Delivery

  2020cites this paper
• Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment

  2020cites this paper
• Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy

  2020cites this paper
• Fusion of Bacterial Flagellin to a Dendritic Cell-Targeting αCD40 Antibody Construct Coupled With Viral or Leukemia-Specific Antigens Enhances Dendritic Cell Maturation and Activates Peptide-Responsive T Cells

  2020cites this paper
• CD40 Agonist Antibodies in Cancer Immunotherapy.

  2020cites this paper
• Isotype selection for antibody‐based cancer therapy

  2020cites this paper
• Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection

  2020cites this paper
• Improved Detection of in vivo Human NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity Using a Novel NOG-FcγR-Deficient Human IL-15 Transgenic Mouse

  2020cites this paper
• ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models

  2020cites this paper
• Inhibition of the Adenosine Pathway to Potentiate Cancer Immunotherapy: Potential for Combinatorial Approaches.

  2020cites this paper
• FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells

  2020cites this paper
• CD40- and CD95-specific antibody single chain-Baff fusion proteins display BaffR-, TACI- and BCMA-restricted agonism

  2020cites this paper
• Domain binding and isotype dictate the activity of anti-human OX40 antibodies

  2020cites this paper
• Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity

  2020influential citation
• Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint.

  2020cites this paper